ContraFect Corporation (CFRX) Getting Somewhat Positive News Coverage, Study Finds
Media stories about ContraFect Corporation (NASDAQ:CFRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ContraFect Corporation earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6115173304682 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Separately, Maxim Group restated a “hold” rating on shares of ContraFect Corporation in a research report on Thursday, May 25th.
ContraFect Corporation (CFRX) traded down 2.2353% during trading on Tuesday, reaching $0.9972. 190,589 shares of the company’s stock traded hands. ContraFect Corporation has a one year low of $0.80 and a one year high of $3.16. The stock’s market cap is $73.45 million. The firm’s 50 day moving average price is $1.13 and its 200-day moving average price is $1.46.
ContraFect Corporation (NASDAQ:CFRX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. On average, equities analysts anticipate that ContraFect Corporation will post ($0.43) earnings per share for the current fiscal year.
In other ContraFect Corporation news, Director Sol J. Barer acquired 40,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was purchased at an average cost of $1.24 per share, for a total transaction of $49,600.00. Following the transaction, the director now owns 815,933 shares of the company’s stock, valued at approximately $1,011,756.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 50,800 shares of company stock valued at $62,992 over the last 90 days. Corporate insiders own 9.30% of the company’s stock.
ContraFect Corporation Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.